BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3113721)

  • 21. Characterization of adult human marrow hematopoietic progenitors highly enriched by two-color cell sorting with My10 and major histocompatibility class II monoclonal antibodies.
    Lu L; Walker D; Broxmeyer HE; Hoffman R; Hu W; Walker E
    J Immunol; 1987 Sep; 139(6):1823-9. PubMed ID: 3114377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thy-1 antigen expression by murine high-proliferative capacity hematopoietic progenitor cells. I. Relation between sensitivity to depletion by Thy-1 antibody and stem cell generation potential.
    Boswell HS; Wade PM; Quesenberry PJ
    J Immunol; 1984 Dec; 133(6):2940-9. PubMed ID: 6149245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Presence of methylthioadenosine phosphorylase (MTAP) in hematopoietic stem/progenitor cells: its therapeutic implication for MTAP (-) malignancies.
    Yu J; Batova A; Shao L; Carrera CJ; Yu AL
    Clin Cancer Res; 1997 Mar; 3(3):433-8. PubMed ID: 9815702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depletion of T cells from human bone marrow with monoclonal antibody CT-2 and complement.
    Trigg ME; Billing R; Sondel PM; Dickerman JD; Erickson C; Finlay JL; Bozdech M; Hong R; Padilla-Nash H; Terasaki P
    J Biol Response Mod; 1984 Aug; 3(4):406-12. PubMed ID: 6384432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serological study for in vitro use of monoclonal antibody for autologous bone marrow transplantation in null cell-type acute lymphocytic leukemia.
    Sao H; Morishima Y; Ueda R; Yoshikawa S; Kodera Y; Ohno R; Takahashi T
    Jpn J Cancer Res; 1985 Dec; 76(12):1212-21. PubMed ID: 3937833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow.
    Uckun FM; Ramakrishnan S; Houston LL
    J Immunol; 1985 Mar; 134(3):2010-6. PubMed ID: 3855433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Depletion of T cells from bone marrow for allogeneic transplantation: method for treatment of bone marrow in bulk.
    Trigg ME; Peterson A; Erickson C; Bozdech M; Billing R; Sondel P; Finlay J; Surfus J; Stuiber M; Hong R
    Exp Hematol; 1986 Jan; 14(1):21-6. PubMed ID: 3080322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined ex vivo treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts.
    Uckun FM; Stong RC; Youle RJ; Vallera DA
    J Immunol; 1985 May; 134(5):3504-15. PubMed ID: 3884712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective removal of clonogenic neoplastic B cells from human bone marrow using anti-HLA-DQ antibodies and complement.
    Falkenburg JH; Fibbe WE; Veenhof WF; Koning F; van Eeden G; Voogt PJ; Jansen J
    Exp Hematol; 1986 Feb; 14(2):101-7. PubMed ID: 2417877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential cytotoxicity of an ether lipid on lymphoma and bone marrow cells and its role in purging malignant lymphoid cells from remission bone marrow contaminated with tumor cells.
    Dietzfelbinger HF; Lang A; Oberberg D; Rastetter JW; Berdel WE
    Exp Hematol; 1992 Feb; 20(2):178-83. PubMed ID: 1544386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of deoxycoformycin on bone marrow cells treated with adenosine and deoxyadenosine and hemopoietic growth factors.
    Fabian I; Williams Z
    Hum Immunol; 1988 Feb; 21(2):81-7. PubMed ID: 3259223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Harvesting, characterization, and culture of CD34+ cells from human bone marrow, peripheral blood, and cord blood.
    Van Epps DE; Bender J; Lee W; Schilling M; Smith A; Smith S; Unverzagt K; Law P; Burgess J
    Blood Cells; 1994; 20(2-3):411-23. PubMed ID: 7538347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres.
    O'Briant KC; Shpall EJ; Houston LL; Peters WP; Bast RC
    Cancer; 1991 Sep; 68(6):1272-8. PubMed ID: 1873781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relative sensitivity of peripheral blood T-lymphocyte colony forming cells and bone marrow CFU-GM to deoxyadenosine and 2'deoxycoformycin.
    Russell NH; Carron J; Hoffbrand AV; Bellingham AJ
    Leuk Res; 1985; 9(2):315-9. PubMed ID: 3872974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture.
    Greenberger JS; Rothstein L; DeFabritiis P; Bregni M; Bast R; Ritz J; Nadler LM; Lipton JM; Sakakeeny MA
    Cancer Res; 1985 Feb; 45(2):758-67. PubMed ID: 3967246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of T lymphocyte subsets and humoral factors on colony formation by human bone marrow and blood megakaryocyte progenitor cells in vitro.
    Geissler D; Lu L; Bruno E; Yang HH; Broxmeyer HE; Hoffman R
    J Immunol; 1986 Oct; 137(8):2508-13. PubMed ID: 3489766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complement depletion in vitro limits monoclonal antibody 6-19-dependent complement-mediated killing of tumor cells in bone marrow.
    Duerst RE; Rose D; Frantz CN
    Exp Hematol; 1991 Oct; 19(9):863-7. PubMed ID: 1893961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement.
    Bast RC; Ritz J; Lipton JM; Feeney M; Sallan SE; Nathan DG; Schlossman SF
    Cancer Res; 1983 Mar; 43(3):1389-94. PubMed ID: 6337707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical evaluation of immunoconjugates consisting of doxorubicin linked to complement-fixing monoclonal antibody DLC-48 for bone marrow purging of B-cell lymphomas.
    Winter JN; Bass B; Bringman T; Nedwin G
    Prog Clin Biol Res; 1990; 333():171-83. PubMed ID: 2408059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T-cell phenotypic profile and colony formation during recovery from cytotoxic therapy-induced marrow aplasia.
    Ashkenazi YJ; Barth KC; Elfenbein GJ
    Cancer Res; 1985 Dec; 45(12 Pt 1):6513-8. PubMed ID: 3933827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.